Microengineered Organ-on-a-chip Platforms towards Personalized Medicine.

Area of Science:

• Biomedical Engineering
• Drug Development
• Toxicology

Background:

• Traditional preclinical drug evaluation relies on oversimplified cell cultures and animal models.
• These methods are time-consuming, lack biological complexity, and show poor human extrapolation.
• Existing models struggle to accurately predict pharmacological and toxicological outcomes.

Purpose of the Study:

• To review organ-on-a-chip (OOC) platforms as advanced tools for preclinical drug evaluation.
• To highlight the integration of microfluidics and 3D tissue engineering for OOC fabrication.
• To discuss the potential of OOCs in drug screening, toxicity testing, and personalized medicine.

Main Methods:

• Review of current limitations in drug development pipelines (screening, in vitro assays, in vivo models).
• Discussion of various OOC platforms, their fabrication using microfluidics and 3D simulations.
• Analysis of OOC applications in preclinical drug testing and personalized medicine.

Main Results:

• OOC platforms biomimetically replicate complex human tissue architecture and physiology.
• These platforms enable more accurate prediction of drug responses and toxicity.
• Integration with 3D simulations enhances the robustness of OOC models for preclinical testing.

Conclusions:

• OOC technology addresses limitations of traditional preclinical models, accelerating drug development.
• OOCs show significant promise for drug screening, toxicity assessment, and personalized medicine.
• Further advances in materials, microfluidics, and commercialization are key for clinical translation.